On this page

Gentamicin Sulfate

Prescription ANDA TE AT Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
Gentamicin Sulfate
Generic name
Gentamicin Sulfate
Dosage form
Solution/ Drops
Route
Ophthalmic
Marketing category
ANDA · ANDA
Labeler
Proficient Rx LP
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
1
NDC product codes
10
Packages
10
Data completeness
82% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Gentamicin Sulfate 3 mg/mL 1870650 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Solution/ Drops
Route of administration
Ophthalmic
Presentations
20

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Aminoglycoside Antibacterial [EPC] EPC All 66 members
Aminoglycosides [CS] CS All 66 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
064048
Application type
ANDA · Abbreviated New Drug Application
Approval date
May 11, 1994
Sponsor
BAUSCH AND LOMB INC
Products on application
1
Submissions recorded
15
Products approved under application 064048.
Product Trade name Form Strength Ingredient Status TE Flags
064048-001 GENTAMICIN SULFATE SOLUTION/DROPS GENTAMICIN SULFATE Prescription AT

Therapeutic equivalence

Source: Orange Book
TE code
AT
Reference Listed Drug
No
Reference Standard
No

What this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 064048.
Type No. Action Status Date Review
Supplement 14 Manufacturing (CMC) Approved November 27, 2001 —
Supplement 13 Manufacturing (CMC) Approved August 29, 2001 —
Supplement 12 Manufacturing (CMC) Approved March 7, 2001 —
Supplement 11 Manufacturing (CMC) Approved October 5, 2000 —
Supplement 10 Manufacturing (CMC) Approved June 27, 2000 —
Supplement 7 Manufacturing (CMC) Approved May 18, 2000 —
Supplement 9 Manufacturing (CMC) Approved May 15, 2000 —
Supplement 8 Manufacturing (CMC) Approved April 28, 2000 —
Supplement 6 Manufacturing (CMC) Approved June 7, 1999 —
Supplement 5 Manufacturing (CMC) Approved November 19, 1998 —
Supplement 4 Manufacturing (CMC) Approved May 4, 1998 —
Supplement 3 Manufacturing (CMC) Approved January 14, 1998 —
Supplement 2 Manufacturing (CMC) Approved August 26, 1996 —
Supplement 1 Manufacturing (CMC) Approved September 9, 1994 —
Original application 1 Approved May 11, 1994 —

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260505). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20260505 HUMAN PRESCRIPTION DRUG · 20240814 HUMAN PRESCRIPTION DRUG · 20240614 HUMAN PRESCRIPTION DRUG · 20240110

Indications and Usage

openFDA Drug Labeling

INDICATIONS & USAGE SECTION Gentamicin sulfate ophthalmic solution, USP is indicated in the topical treatment of ocular bacterial infections including conjunctivitis, keratitis, keratoconjunctivitis, corneal ulcers, blepharitis, blepharoconjunctivitis, acute meibomianitis, and dacryocystitis, caused by susceptible strains of the following microorganisms: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, Enterobacter aerogenes, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Neisseria gonorrhoeae, Pseudomonas aeruginosa, and Serratia marcescens.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION Gentamicin Sulfate sterile ophthalmic solution; Instill one or two drops into the affected eye(s) every four hours. In severe infections, dosage may be increased to as much as two drops once every hour.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS SECTION Gentamicin sulfate ophthalmic solution, USP is contraindicated in patients with known hypersensitivity to any of its components.

WARNINGS SECTION NOT FOR INJECTION INTO THE EYE. Gentamicin sulfate ophthalmic solution, USP is not for injection. It should never be injected subconjunctivally, nor should it be directly introduced into the anterior chamber of the eye.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS Bacterial and fungal corneal ulcers have developed during treatment with gentamicin ophthalmic preparations. The most frequently reported adverse reactions are ocular burning and irritation upon drug instillation, non-specific conjunctivitis, conjunctival epithelial defects and conjunctival hyperemia. Other adverse reactions which have occurred rarely are allergic reactions, thrombocytopenic purpura and hallucinations. To report SUSPECTED ADVERSE REACTIONS, contact Bausch & Lomb Incorporated at 1-800-553-5340 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Description

openFDA Drug Labeling

DESCRIPTION Gentamicin sulfate ophthalmic solution, USP is a sterile, topical anti-infective agent for ophthalmic use. Gentamicin is obtained from cultures of Micromonospora purpurea . It is a mixture of the sulfate salts of gentamicin C 1 , C 2 , and C 1A . All three components appear to have similar antimicrobial activity. Gentamicin sulfate occurs as a white to buff powder and is soluble in water and insoluble in alcohol. The structural formula is as follows: Each mL contains: Active: gentamicin sulfate equivalent to 3 mg (0.3%) gentamicin base. Preservative: benzalkonium chloride. Inactives: edetate disodium; polyvinyl alcohol 1.4%; purified water; sodium chloride; sodium phosphate, dibasic; and hydrochloric acid and/or sodium hydroxide may be added to adjust pH. The solution is an aqueous, buffered solution with a shelf life pH range of 6.5 to 7.5. The structural formula for Gentamicin is obtained from cultures of Micromonospora purpurea. It is a mixture of the sulfate salts of gentamicin C1, C2, and C1A. All three components appear to have simi

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED Gentamicin sulfate ophthalmic solution USP, 0.3% is supplied sterile in a white LDPE plastic bottle, with a white LLDPE extended controlled drop tip and white polypropylene cap in the following size: NDC 68788-8592-5- 5 mL NOT FOR INJECTION INTO THE EYE FOR OPHTHALMIC USE ONLY Storage: Store between 2°C to 25°C (36°F to 77°F). Avoid exposure to excessive heat. KEEP OUT OF REACH OF CHILDREN. Distributed by: Bausch & Lomb Americas Inc. Bridgewater, NJ 08807 USA Manufactured by: Bausch & Lomb Incorporated Tampa, FL 33637 USA © 2022 Bausch & Lomb Incorporated or its affiliates Revised: September 2022 9116006 (Folded) 9116106 (Flat) Relabeled By: Preferred Pharmaceuticals Inc. donotuse

Adverse event reports

Source: openFDA FAERS
15,708
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: GENTAMICIN SULFATE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
50090-0569-0 50090-0569 A-S Medication Solutions 1 BOTTLE, DROPPER in 1 CARTON (50090-0569-0) / 5 mL in 1 BOTTLE, DROPPER June 29, 2016
76420-254-05 76420-254 Asclemed USA, Inc. 1 BOTTLE, DROPPER in 1 CARTON (76420-254-05) / 5 mL in 1 BOTTLE, DROPPER July 19, 2022
24208-580-60 24208-580 Bausch & Lomb Incorporated 1 BOTTLE, DROPPER in 1 CARTON (24208-580-60) / 5 mL in 1 BOTTLE, DROPPER May 11, 1994
61919-106-05 61919-106 DIRECT RX 5 mL in 1 CARTON (61919-106-05) May 7, 2015
66267-971-05 66267-971 NuCare Pharmaceuticals, Inc. 1 BOTTLE, DROPPER in 1 CARTON (66267-971-05) / 5 mL in 1 BOTTLE, DROPPER March 16, 2017
68071-3554-5 68071-3554 NuCare Pharmaceuticals,Inc. 1 BOTTLE, DROPPER in 1 CARTON (68071-3554-5) / 5 mL in 1 BOTTLE, DROPPER December 7, 2023
68071-4827-5 68071-4827 NuCare Pharmaceuticals,Inc. 5 mL in 1 BOX (68071-4827-5) March 29, 2019
68788-8592-5 68788-8592 Preferred Pharmaceuticals Inc. 1 BOTTLE, DROPPER in 1 CARTON (68788-8592-5) / 5 mL in 1 BOTTLE, DROPPER February 22, 2024
63187-560-05 63187-560 Proficient Rx LP 1 BOTTLE, DROPPER in 1 CARTON (63187-560-05) / 5 mL in 1 BOTTLE, DROPPER December 1, 2018
63187-764-05 63187-764 Proficient Rx LP 1 BOTTLE, DROPPER in 1 CARTON (63187-764-05) / 5 mL in 1 BOTTLE, DROPPER November 1, 2016
50090-0569 50090-0569 A-S Medication Solutions — May 11, 1994
76420-254 76420-254 Asclemed USA, Inc. — May 11, 1994
24208-580 24208-580 Bausch & Lomb Incorporated — May 11, 1994
61919-106 61919-106 DIRECT RX — January 1, 2014
66267-971 66267-971 NuCare Pharmaceuticals, Inc. — December 13, 2006
68071-3554 68071-3554 NuCare Pharmaceuticals,Inc. — May 11, 1994
68071-4827 68071-4827 NuCare Pharmaceuticals,Inc. — January 5, 1998
68788-8592 68788-8592 Preferred Pharmaceuticals Inc. — February 22, 2024
63187-560 63187-560 Proficient Rx LP — May 11, 1994
63187-764 63187-764 Proficient Rx LP — December 13, 2006

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 12 sections on this page.